Communiqués Actinium Pharmaceuticals, Inc.

Actions

ATNM

US00507W2061

Marché Fermé - Nyse Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
7,4 ^USD	+0,14%		+1,23%	+45,67%

14/06	Actinium Pharmaceuticals, Inc. souligne la présentation orale au congrès annuel de l'EHA 2024 de l'amélioration des résultats chez les patients TP53 positifs recevant de l'Iomab-B dans l'étude de phase 3 SIERRA	CI
11/06	Actinium annonce les résultats de l'essai combiné Actimab-A + CLAG-M présentés oralement lors de la réunion annuelle 2024 de la Society of Nuclear Medicine & Molecular Imaging	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models	18/06	AQ
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions	18/06	NE
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial	17/06	AQ
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)	17/06	NE
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting	12/06	AQ
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside	09/05	AQ
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML	19/04	AQ
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest	17/04	AQ
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation	02/04	AQ
InvestorBrandMedia: Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSEAMERICAN: ATNM) Amidst Groundbreaking Cancer Therapy Innovations	01/04	AQ
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey	28/03	AQ
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy	27/03	AQ
InvestorBrandMedia: FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease"	25/03	AQ
InvestorBrandMedia: Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge	21/03	AQ
InvestorBrandMedia: Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225	20/03	AQ
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial	27/02	AQ
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings	26/02	AQ
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings, Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR	03/01	AQ
Actinium s Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia	12/12	AQ
Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation	12/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Actinium Pharmaceuticals, Inc.

Actions

ATNM

US00507W2061

Communiqués

Filtres